1. Response time (Time Frame - 84 day +/- 6 days): Response time in seconds obtained during trail-making test (ePRO) according to daily administration via consilium careTM app, as a potential indicator for ICANS and other CAR T cell therapy-related adverse events.
Secondary outcome:
1. Occurrence of CRS-related adverse events (ePRO) (Time Frame - 84 day +/- 6 days): Occurrence of CRS-related adverse events (ePRO): fever, myalgia, rigors, fatigue, and loss of appetite
2. Number and severity of adverse events (AE) according to the CTCAE (Time Frame - 84 day +/- 6 days): Number and severity of adverse events (AE) according to the Common Terminology Criteria for Adverse Events (CTCAE) after 12 weeks (ePRO).
CTCAE on a 5 point scale: Grade 1 is mild, grade 2 moderate, grade 3 severe, grade 4 life-threatening, and grade 5 corresponds to death. Grade 3 and higher correspond to the WHO definition of serious adverse drug reaction ("serious ADR").
3. Occurrence and type of therapy-associated unplanned consultations (Time Frame - 84 day +/- 6 days): Occurrence and type of therapy-associated unplanned consultations. Unplanned consultations are defined as additional consultations outside of planned therapy or control visits at the treatment center or with the investigator, as well as unplanned visits to other physicians or emergency services.
4. Adherence (Time Frame - 84 day +/- 6 days): Adherence, measured as percentage of days during intervention with electronically captured consilium careTM app usage
5. Well-being (Time Frame - 84 day +/- 6 days): Well-being according to the ECOG Performance Status as daily ePRO before and after CAR T cell reinfusion.
